Technology to Reduce Motion Sickness in Marine Corps Amphibious Vehicles

Hyundai Mobis has implemented its cutting-edge vehicle healthcare technology into the Republic of Korea Marine Corps amphibious assault vehicles. 

This technology is expected to alleviate motion sickness for marines traversing rough terrains from sea to land, enhancing combat performance.

Hyundai Mobis has signed a Memorandum of Understanding (MoU) with the RoK Marine Corps for ‘Cooperation in Motion Sickness Reduction Technology.’

Last year, Hyundai Mobis developed the ‘Smart Cabin Controller,’ analyzing a driver’s posture, heart rate, and brainwaves to prevent drowsiness, stress, and motion sickness. This collaboration with the Marine Corps is expected to further advance motion sickness reduction technology to help marines traverse challenging terrains and withstand other harsh conditions.

This marks the first application of Hyundai Mobis’ motion sickness reduction technology in the broader mobility sector beyond conventional vehicles. Its introduction is anticipated to expand into defense, maritime, and aviation transportation.

Hyundai Mobis’ motion sickness reduction technology integrates autonomous driving with passenger cognitive technologies. Especially the latter involves real-time monitoring of posture, heart rate, and brainwaves using sensors. Based on this biometric data, simulating the senses of sight, hearing, smell, and touch can minimize motion sickness. According to Hyundai Mobis, this technology can prevent motion sickness by up to 70% and reduce the symptoms by 40%.

Hyundai Mobis will provide the Marine Corps with an integrated motion sickness reduction solution tailored for harsh environments, combining hardware and software. The solution includes movement-analysis sensors, environmental perception sensors, and control solutions. It also features displays allowing passengers to easily view travel information (visual) and climate control modules that stabilize passengers with cool air (tactile).

Hyundai Mobis plans to operate this technology in amphibious assault vehicles and, in collaboration with the Marine Corps, gather key data by the first half of next year. The company aims to deploy it in combat training and systematically analyze motion sickness-inducing factors to enhance the technology’s efficacy.